Topic

Articles

Pharma industry welcomes announcement of a draft withdrawal agreement, stating it is an important step towards securing a Brexit deal.

Pharmaceutical Industry Welcomes an Important Step Toward Securing a Brexit Deal, Says ABPI

The agency provided an update on its relocation plans and assured that core activities are continuing uninterrupted.

EMA Gives Update on Brexit Plans

The latest Manufacturing Barometer report, published by SWMAS, indicates concern over Brexit by UK manufacturers and an anticipation of lower business growth over the next six months.

Manufacturers’ Brexit Concerns Reflected in Lowest Growth Expectation in Six Years

This article explores major aspects for United States biotech companies to consider when creating a compliant post-Brexit strategy.

Strategies for Managing the Impact of Brexit for US Biotech Companies

The Medicines and Healthcare products Regulatory Agency (MHRA) has opened a consultation to seek views on how legislations and procedures of the agency may need to be modified should there be a ‘no-deal’ Brexit scenario.

MHRA Seeks Views on ‘No-Deal’ Brexit Legislation and Procedural Changes

As Europe and the United Kingdom are facing the ever-expanding shadow of Brexit, a keynote session taking place at CPhI Worldwide in Madrid will look to assess the wider implications of the UK’s exit from the European Union on the Pharma sector.

Wider Implications of Brexit on Pharma

The European Medicines Agency revised the number of centrally authorized medicines for which there are concerns over Brexit-related supply disruptions.

Companies Stepping Up Efforts to Ensure Medicine Supply Post-Brexit

Guidances for regulatory changes, batch testing, and reporting address situations resulting from “no-deal” Brexit scenario.

UK Outlines Potential Pharma Changes Post-Brexit

The European Medicines Agency (EMA) will temporarily scale back activities as it copes with “significant staff loss” and prepares for the next phase in its continuity plan.

EMA Scales Back Activities to Prepare for Brexit

Findings from a survey show that some companies have not yet taken the necessary steps to ensure the continuity of medicine supply in the European Union after the United Kingdom’s departure.

Bio/Pharma and Brexit